<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20121228011912N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-10</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of standard treatment of classical medicine and embedding in controlling dysmenorrhea and dyspareunia caused by endometriosis in women</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of standard treatment of classical medicine and embedding in controlling dysmenorrhoea and dysparonychia caused by endometriosis in women.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69650</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the online site https://www.sealedenvelope.com, random allocation will be placed in two groups: A, classical medicine, and B, embedding. Randomization will be done based on Block Randomization with blocks of 4. The random allocation of 12 blocks of 4 will be as follows. The prepared blocks will be placed in the envelope. One of the envelopes will be randomly selected according to the order of patients' arrival, and based on the obtained blocks, 4 patients will be assigned to two groups, Blinding description: Using the online site https://www.sealedenvelope.com, random allocation will be placed in two groups: A, classical medicine, and B, embedding. Randomization will be done based on Block Randomization with blocks of 4. The random allocation of 12 blocks of 4 will be as follows. The prepared blocks will be placed inside the envelope. According to the order of patients' entry, one of the envelopes will be randomly selected and based on the obtained blocks, 4 patients will be assigned to two groups. Then, the collaboration, which is blind to the type of interventions, will check all patients in terms of entry and exit criteria, and then Forms and questionnaires are completed and primary and secondary outcomes are determined for those eligible.</study_design>
      <phase>3</phase>
      <hc_freetext>dysmenorrhea and dyspareunia caused by endometriosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Embedding in women with dysmenorrhoea and dysparonychia caused by endometriosis in reproductive age. Acupuncture embedding is a new and emerging method developed in the fields of acupuncture and embedding needle. This method has immediate and long-lasting effects on the human body, compensates for the short duration of acupuncture stimulation and reduces the number of times patients visit the doctor. Intervention 2: Intervention group: Intervention group: The classical medicine group will be treated with one continuous and regular daily LD pill for a period of three months and from the same day (the first day of the menstrual cycle).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The statistical details of the data will be mentioned in the published article.

When:
After finishing research

To whom:
All those who have access to the published article or with the supervisory permission of the Vice Research of Mashhad University of Medical Sciences

Conditions:
With the request of the responsible researcher and the consent of the University Research Council and only for survey purposes without any possibility of exploiting the content of the data.

Where to obtain:
After printing the article to the responsible author and before printing, if required by relevant authorities, to the responsible researcher

How to obtain:
By means if Vice research of Mashhad University of Medical Science

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Hamidreza Bahrami-Taghanaki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ebne Sina Street</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9184166750</zip>
        <telephone>+98 51 3884 8931</telephone>
        <email>bahramihr@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Hamidreza Bahrami-Taghanaki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ebne Sina street</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9184166750</zip>
        <telephone>+98 51 3841 1538</telephone>
        <email>bahramihr@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of clinical endometriosis by observing pain and tenderness in the pelvic examination along with endometriosis nodules in the vaginal examination, firm and motionless uterus and confirmed by ultrasound or MRI (observation of endometriosis cysts and nodules)
Diagnosis of grade I-IV endometriosis based on r-ASRM criteria during diagnostic laparoscopy during the previous 12 months
Dysmenorrhea complaint with EAPP score &gt;30 or &gt;40
normal pap smear
Age 18-45 years
Informed written consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unwillingness to continue the research
Non-adherence to the provided treatment regimen and incorrect or incomplete use of medication
Occurrence of any complications attributed to drug use (especially allergies)
Endometriosis who were treated with GNRH agonist less than 6 months ago, or danazol or progesterone pills less than 3 months ago, or birth control pills less than one month ago
Breastfeeding, pregnancy. Cancers of the uterus, ovaries, cervix and high-grade intraepithelial lesions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N80.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Endometriosis, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Embedding in women with dysmenorrhoea and dysparonychia caused by endometriosis in reproductive age. Acupuncture embedding is a new and emerging method developed in the fields of acupuncture and embedding needle. This method has immediate and long-lasting effects on the human body, compensates for the short duration of acupuncture stimulation and reduces the number of times patients visit the doctor.</i_keyword>
      <i_keyword>Intervention group: Intervention group: The classical medicine group will be treated with one continuous and regular daily LD pill for a period of three months and from the same day (the first day of the menstrual cycle).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Dysmenorrhea and dyspareunia. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months later. Method of measurement: It will be evaluated using the EAPP checklist scale.</prim_outcome>
      <prim_outcome>Anti-Müllerian hormone serum level and antral follicle count. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months later. Method of measurement: Measurement of anti-Müllerian hormone serum level and antral follicle count by ultrasound.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of Life. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months later. Method of measurement: Short form of World Health Organization quality of life questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-07</approval_date>
        <contact_name>Mashhad University of Medical Sciences (Research Ethics Committee)</contact_name>
        <contact_address>3rd floor - Abuzar qafari Bulv - Abuzar qafari 38- Ahmad Abad Ave. mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
